NCT04059783View on ClinicalTrials.gov

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

CompletedOBSERVATIONAL
Enrollment

272

Participants

Timeline

Start Date

June 17, 2008

Primary Completion Date

April 27, 2010

Study Completion Date

February 20, 2011

Conditions
Functional Gastrointestinal Disorders
Interventions
DRUG

STW5 (Iberogast®, BAY98-7411)

The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04059783 - Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function | Biotech Hunter | Biotech Hunter